Loading...
•
Mar 31, 2021
Ionis Q1 2021 Earnings Report
Ionis reported financial results for Q1 2021, highlighting progress in maximizing the value of its wholly owned pipeline and strengthening its balance sheet.
Key Takeaways
Ionis Pharmaceuticals reported $112 million in total revenues for Q1 2021. The company has strengthened its balance sheet with a pro forma cash of $2.1 billion. They are on track to achieve their 2021 financial guidance, reflecting investments in Ionis’ wholly owned pipeline.
Total revenues reached $112 million.
Operating expenses were $159 million on a non-GAAP basis and $204 million on a GAAP basis.
Net loss was $45 million on a non-GAAP basis and $90 million on a GAAP basis.
Pro forma cash reached $2.1 billion after reflecting the convertible notes transaction.
Revenue by Segment
Forward Guidance
Ionis is on track to achieve its 2021 financial guidance and expects R&D revenue to increase in the second half of the year.
Positive Outlook
- On track to achieve 2021 financial guidance.
- Expect R&D revenue to increase in the second half of 2021.
- Well-capitalized with resources to expand manufacturing and R&D capacity.
- Completing restructuring of European operations and expanded Sobi distribution agreement to include North America.
- Redirecting resources towards highest priority programs, including IONIS-TTR-LRx and IONIS-APOCIII-LRx.
Challenges Ahead
- Operating expenses increased due to investments in the late-stage wholly owned pipeline.
- Net loss attributable to Ionis common stockholders increased compared to the same period in the prior year.
- Incurred $7 million of costs related to the Akcea acquisition and restructured European operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...